HIV vaccine trial

by ARTiFactor on Nov. 05th, 2007

Over 90 per cent of the subjects in the phase 1 trials developed an immune response to HIV. The study was conducted by researchers at Karolinska Institutet (KI), Karolinska University Hospital and the Swedish Institute for Infectious Disease Control (SMI).
Read more about the results from Swedish study of HIV vaccine at the Karolinska Institutet web site.

Your Comments, Thoughts, Questions, Ideas

Anonymous's picture
Anonymous says:

Suppression of human immunodeficiency virus type 1 viral load with selenium supplementation: a randomized controlled trial. Hurwitz BE, et al.

"CONCLUSIONS: Daily selenium supplementation can suppress the progression of HIV-1 viral burden and provide indirect improvement of CD4 count. The results support the use of selenium as a simple, inexpensive, and safe adjunct therapy in HIV spectrum disease." And this was only with 200 mcg of selenium, where it is safe to take 800 mcg per day.

posted on Mon, 11/05/2007 - 1:19pm
ARTiFactor's picture
ARTiFactor says:

This HIV vaccine trial did not use selenium supplementation.

The vaccine is what is known as a genetic vaccine, which uses parts of the virus DNA to stimulate the rapid endogenous production of the proteins for which the injected DNA codes.

posted on Tue, 11/06/2007 - 9:33am
Simon's picture
Simon says:

Hope the HIV vaccine is helpful to me. I read this news on before. Seems many people are interested.

posted on Mon, 11/05/2007 - 6:27pm

Post new comment

The content of this field is kept private and will not be shown publicly.
  • Allowed HTML tags: <a> <h3> <h4> <em> <i> <strong> <b> <span> <ul> <ol> <li> <blockquote> <object> <embed> <param> <sub> <sup>
  • Lines and paragraphs break automatically.
  • You may embed videos from the following providers vimeo, youtube. Just add the video URL to your textarea in the place where you would like the video to appear, i.e.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Images can be added to this post.

More information about formatting options